The cornea developed severe central haze with decrease of vision to 2.0 logMAR with a refraction of À 1.0E À 2.5/180 6 months later (Figure 1a ). MMC 0.02% was applied therefore as a therapeutic option for 45 s on a sponge after epithelial removal. 2 Haze disappeared 4 months later and UDVA increased to 0.2 logMAR. The cornea remained clear for the follow-up period of 21 months ( Figure 1b ).
Sir,

Intra-lesional interferon injection for recurrent conjunctival MALT lymphoma
Conjunctival mucosa-associated lymphoid tissue (MALT) lymphomas are localized low-grade extra-nodal tumours that are managed with radiotherapy, cryotherapy, surgical excision, or even observation.
Intra-lesional interferon injection for conjunctival lymphomas was first cited as early as 1996 by Cellini et al; 1 its successful use has been reported since then. 2, 3 We report a case where its use has been invaluable in a patient with recurrent conjunctival MALT lymphoma following external beam radiation.
Case report
A 55-year-old woman presented with a 2-week history of red watery right eye and swelling of her right lower lid. On examination, she had a salmon pink mass in the right inferior bulbar conjunctiva (Figure 1a ). The rest of the ocular examination was normal. Conjunctival biopsy confirmed this to be an extra-nodal marginal-zone MALTtype lymphoma. The patient was treated with external beam radiation (24 Gy in 12 fractions) to the right inferior conjunctiva with complete regression of the lymphoma.
At 10 months post radiotherapy, she was noted to have a similar pink lesion in the right superior bulbar conjunctiva (Figure 1b) . A biopsy confirmed recurrent MALT lymphoma (Figure 1c ).
Owing to recent external beam radiotherapy it was felt inappropriate to re-treat her with the same modality and she was treated with intra-lesional interferon injection.
She received a 4-week course of 3 times a week intralesional injections of 1.5 mega-units in 0.25 ml of Interferon a2A, with complete regression of the lesion.
She remains disease free at 10 months follow-up. Eye Comment Radiotherapy has been widely used as a treatment for MALT lymphoma with successful results, but ocular complications such as corneal ulcers, radiation-induced cataract, ocular surface disorders, 4 and recurrence have been reported. Intra-lesional interferon has been successfully used for treatment of conjunctival MALT lymphoma. A recurrence rate of 15% on a long-term follow-up (65 months) has been reported. 5 We believe this is the first case reported where intralesional Interferon a2A was used in recurrent conjunctival MALT lymphoma after external beam radiation, and we recommend considering it in similar cases.
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Case report
A 37-year-old male attended the ophthalmology department seeking treatment for a cosmetically, unsightly dark area in the medial aspect of the left eye, resulting from previous medial rectus recession surgery. The dark area developed during the year following the squint operation. There was no history of post-operative scleritis. Examination showed a dark scleral area of 3 mm Â 11 mm, located 6 mm nasally from the limbus (Figure 1a) .
The patient was offered a surgical procedure to cover the area of dark sclera with a Tutoplast pericardium graft. A localised peritomy was performed to expose the area of interest (Figure 1b) . A Tutoplast pericardial graft, which is thinner than sclera but of similar colour and opacity, was placed over this area and fixed to the sclera with 8/0 Vicryl sutures (Figure 1c) . The conjunctiva was closed with interrupted 7/0 Vicryl sutures (Figure 1d) .
At 2-week follow-up, the patient reported no pain or significant discomfort, and was satisfied with the cosmetic result of the surgery. Objective examination demonstrated a minimally visible area of previously overtly dark sclera and mild conjunctival injection. This excellent cosmesis was retained at 6 months ( Figure 2b ). Figure 1 Photographs of the left eye of the patient prior to the scleral patch graft (a), intraoperative images of the exposed area of the dark sclera (b), placement of the Tutoplast pericardium over the unsightly dark sclera (c), and after the closure of conjunctival wound (d).
